DIABETES MELLITUS TIPO 2: HIPOGLICEMIANTES ORALES

Evens Chong; Waldo Herrera

Enviado noviembre 5, 2024

Publicado 2026-04-06

Artículos de Investigación

Vol. 15 Núm. 1 (2002): Revista Médico Científica

DIABETES MELLITUS TIPO 2: HIPOGLICEMIANTES ORALES

Evens Chong⁺⁻
Waldo Herrera⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-04-06

Cómo citar

1.

Chong E, Herrera W. DIABETES MELLITUS TIPO 2: HIPOGLICEMIANTES ORALES. rmc [Internet]. 6 de abril de 2026 [citado 18 de octubre de 2026];15(1):38-42. Disponible en: https://revistas.up.ac.pa/index.php/revistamedicocientifica/article/view/6248

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

La diabetes mellitus tipo 2, un desorden metabólico crónico que afecta aproximadamente al 90% de los pacientes diabéticos, se define como una enfermedad caracterizada por una deficiencia de secreción de la insulina, resistencia a su acción y aumento de la gluconeogénesis. El tratamiento dirigido a estos defectos metabólicos en múltiples sitios de acción, incluyendo el páncreas, hígado, músculo esquelético, tejido adiposo y tracto gastrointestinal, provee un adecuado control glicémico. La terapia debe elegirse de acuerdo a las necesidades de cada paciente. Actualmente existen diferentes clases de hipoglicemiantes orales. Estas son las sulfonilureas, meglitinidas, derivados de la D-fenilalanina, biguanidas, tiazolidinedionas y los inhibidores de la a-glucosidasa. Además, es común el uso de tratamiento combinado en el manejo de la hiperglicemia en pacientes con diabetes mellitus tipo 2.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63:1747-56.
Masharani U, Karma JH. Diabetes mellitus & hypoglycemia. In: Tierney LM, McPhee S, Papadakis M, editors. Current medical diagnosis & treatment 2002. 41st ed. United States of America: McGraw Hill; 2002. p. 1212-8.
American Diabetes Association Expert Committee. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183.
Amos AF, McCarty DJ, Zimmer P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(Suppl 5):1-85.
Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care. 1998;21(Suppl 3):C3.
Palumbo PJ. Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-18.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
White RJ, Campbell RK. Recent developments in the pharmacological reduction of blood glucose in patients with type 2 diabetes. Clin Diabetes. 2001;19:153-9.
Cincinati R, Veliks J. Oral medications. Medical Economics. 2001;64:30-6.
Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UKPDS. Am Heart J. 1999;138:346-52.
Lebovitz HE. Insulin secretagogues: sulfonylureas and meglitinides. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 326-34.
Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001;358:1709.
Drexel AJ, Robertson C. Type 2 diabetes: How new insights, new drugs are changing clinical practice. Geriatrics. 2001.
Gale EAM. Lessons from the glitazones: A story of drug development. The Lancet. 2001;357:1870-5.
Krentz AJ, Bailey C, Melander A. Thiazolidinediones for type 2 diabetes. BMJ. 2000;321:252-3.
Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.

Palabras clave

PDF

Resumen visto - 174 veces
PDF descargado - 1

Licencia

Content Top

[1] Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63:1747-56.

[2] Masharani U, Karma JH. Diabetes mellitus & hypoglycemia. In: Tierney LM, McPhee S, Papadakis M, editors. Current medical diagnosis & treatment 2002. 41st ed. United States of America: McGraw Hill; 2002. p. 1212-8.

[3] American Diabetes Association Expert Committee. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183.

[4] Amos AF, McCarty DJ, Zimmer P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(Suppl 5):1-85.

[5] Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care. 1998;21(Suppl 3):C3.

[6] Palumbo PJ. Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-18.

[7] United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

[8] White RJ, Campbell RK. Recent developments in the pharmacological reduction of blood glucose in patients with type 2 diabetes. Clin Diabetes. 2001;19:153-9.

[9] Cincinati R, Veliks J. Oral medications. Medical Economics. 2001;64:30-6.

[10] Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UKPDS. Am Heart J. 1999;138:346-52.

[11] Lebovitz HE. Insulin secretagogues: sulfonylureas and meglitinides. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 326-34.

[12] Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001;358:1709.

[13] Drexel AJ, Robertson C. Type 2 diabetes: How new insights, new drugs are changing clinical practice. Geriatrics. 2001.

[14] Gale EAM. Lessons from the glitazones: A story of drug development. The Lancet. 2001;357:1870-5.

[15] Krentz AJ, Bailey C, Melander A. Thiazolidinediones for type 2 diabetes. BMJ. 2000;321:252-3.

[16] Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.

Imagen de portada